FDA Approval for WEZLANA issued to AMGEN INC
Stocks in this Quantisnow insightHealth Care
Historical context for AMGN
Across the 26 sessions after earlier AMGN headlines, the stock closed higher 16 times and lower 10 times, with a median move of 1.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | AMGN | SPY |
|---|---|---|---|
| May 14, 2026 | FDA Approval for WEZLANA issued to AMGEN INCand 2 other headlines that session | -0.1% | +0.8% |
| May 8, 2026 | AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCE | +0.8% | +0.8% |
| May 5, 2026 | Amgen downgraded by Erste Group | +1.8% | +0.8% |
| May 4, 2026 | AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR | -1.8% | -0.4% |
| May 1, 2026 | AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS | -4.7% | +0.3% |
| Apr 30, 2026 | FDA Approval for PAVBLU issued to AMGEN INC | +2.4% | +1.0% |
Quantisnow market dataNASDAQ
AMGN
Amgen Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 1983
Get push alerts for AMGN
Full AMGN profile on Quantisnow Follow AMGN and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time